title: Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
source: Yahoo
date: 2025-10-07
url: https://finnhub.io/api/news?id=53c7ced028caa008897d3d799fc2a989b0f1df85192061fb2770fc37a4eed18b
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
